EE195 Quantifying the Avoided Costs of a Switch to Ofatumumab From Low/Moderate Efficacy Disease Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis in Colombia
Abstract
Authors
M. Ceballos González P. Castro